Targeting of neuroinflammation by glibenclamide in Covid-19: old weapon from arsenal

GES Batiha, HM Al-Kuraishy, AI Al-Gareeb… - …, 2023 - Springer
Abstract In coronavirus disease 2019 (Covid-19) era, neuroinflammation may develop due
to neuronal tropism of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) …

Neuroinflammation and Its Impact on the Pathogenesis of COVID-19

MM Almutairi, F Sivandzade, TH Albekairi… - Frontiers in …, 2021 - frontiersin.org
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). The clinical manifestations of COVID-19 …

Targeting neurological manifestations of coronaviruses by candidate phytochemicals: a mechanistic approach

S Fakhri, S Piri, MB Majnooni, MH Farzaei… - Frontiers in …, 2021 - frontiersin.org
The novel coronavirus 2019 (COVID-19) caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) has made a wide range of manifestations. In this regard …

The anti-inflammatory effect of the tricyclic antidepressant clomipramine and its high penetration in the brain might be useful to prevent the psychiatric consequences …

B Nobile, M Durand, E Olié, S Guillaume… - Frontiers in …, 2021 - frontiersin.org
At the time of writing (December 2020), coronavirus disease 2019 (COVID-19) has already
caused more than one million deaths worldwide, and therefore, it is imperative to find …

Neuropathophysiology of coronavirus disease 2019: neuroinflammation and blood brain barrier disruption are critical pathophysiological processes that contribute to …

MO Welcome, NE Mastorakis - Inflammopharmacology, 2021 - Springer
Abstract Coronavirus disease 2019 (COVID-19) is caused by the novel SARS-CoV-2
(severe acute respiratory syndrome coronavirus 2) first discovered in Wuhan, Hubei …

Neurological consequences of SARS-CoV-2 infection and concurrence of treatment-induced neuropsychiatric adverse events in COVID-19 patients: navigating the …

P Borah, PK Deb, B Chandrasekaran… - Frontiers in molecular …, 2021 - frontiersin.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binds to the angiotensin-
converting enzyme 2 (ACE2) receptor and invade the human cells to cause COVID-19 …

Neuroprotective agents with therapeutic potential for COVID-19

CA Zaa, C Espitia, KL Reyes-Barrera, Z An… - Biomolecules, 2023 - mdpi.com
COVID-19 patients can exhibit a wide range of clinical manifestations affecting various
organs and systems. Neurological symptoms have been reported in COVID-19 patients …

[HTML][HTML] Neurological sequela and disruption of neuron-glia homeostasis in SARS-CoV-2 infection

MG Savelieff, EL Feldman, AM Stino - Neurobiology of disease, 2022 - Elsevier
Abstract The coronavirus disease 2019 (COVID-19) pandemic is responsible for 267 million
infections and over 5 million deaths globally. COVID-19 is caused by severe acute …

SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein

EA Albornoz, AA Amarilla, N Modhiran, S Parker… - Molecular …, 2023 - nature.com
Abstract Coronavirus disease-2019 (COVID-19) is primarily a respiratory disease, however,
an increasing number of reports indicate that SARS-CoV-2 infection can also cause severe …

Neurological manifestation of SARS-CoV-2 induced inflammation and possible therapeutic strategies against COVID-19

D Kumar, S Jahan, A Khan, AJ Siddiqui… - Molecular …, 2021 - Springer
There are regular reports of extrapulmonary infections and manifestations related to the
ongoing COVID-19 pandemic. Coronaviruses are potentially neurotropic, which renders …